4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of “Moderate Buy” from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $29.8750.

A number of equities research analysts recently issued reports on FDMT shares. Chardan Capital reiterated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research report on Friday, May 8th. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Finally, Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th.

4D Molecular Therapeutics Price Performance

FDMT stock opened at $13.00 on Friday. The company has a market capitalization of $679.64 million, a price-to-earnings ratio of -5.06 and a beta of 2.70. 4D Molecular Therapeutics has a 12 month low of $3.86 and a 12 month high of $14.00. The firm has a 50 day moving average of $9.87 and a two-hundred day moving average of $9.23.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. On average, research analysts expect that 4D Molecular Therapeutics will post -4.14 EPS for the current fiscal year.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This represents a 53.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Kirn sold 114,746 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the transaction, the insider owned 942,485 shares in the company, valued at $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 126,478 shares of company stock worth $1,338,369. Corporate insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at about $41,000. Daiwa Securities Group Inc. lifted its position in shares of 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares during the last quarter. Susquehanna Portfolio Strategies LLC bought a new stake in 4D Molecular Therapeutics during the 4th quarter valued at approximately $77,000. Martingale Asset Management L P boosted its stake in 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares during the period. Finally, Gabelli Funds LLC acquired a new stake in 4D Molecular Therapeutics in the 4th quarter valued at approximately $90,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.